Dateline City:
KENILWORTH, N.J.
Congress Highlights Include Results from Trials in a Wide Range of HCV Patients -- Patients with Chronic Kidney Disease, HIV Co-infection, Cirrhosis, and Prior Treatment Failures
Company Remains on Track for NDA Filing with the U.S. FDA During First Half of 2015
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced that grazoprevir/elbasvir, an investigational single
tablet regimen for the treatment of chronic hepatitis C virus (HCV)
infection, has received two new Breakthrough Therapy designations from
the U.S.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 908-740-1871orInvestors:Joe Romanelli, 908-740-1879Justin Holko, 908-740-1986
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more